| Drug ID: | Drug157 |
|---|---|
| Drug Name: | Iron Sucrose |
| CID: | 91663255 |
| DrugBank ID: | DB09146 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00810030, , NCT01067547 |
| Molecular Formula: | C12H29Fe5Na2O23 |
| Molecular Weight: | 866.5 g/mol |
| Isomeric SMILES: | C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO)O)O)O)O.O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3] |
| Synonyms: | Iron sucrose; Saccharated ferric oxide; Iron sugar; Saccharated iron; Saccharated iron oxide; Sucroferric oxyhydroxide; Ferrivenin; Feojectin; Hippiron; Ferric oxide, saccharated |
| Phase 0: | 1 |
| Phase 1: | 17 |
| Phase 2: | 25 |
| Phase 3: | 28 |
| Phase 4: | 36 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1202 | 91663255 | Sucroferric oxyhydroxide | 596 | BCL2 | Bos taurus (cattle) | 16957011 | Ferric oxide, saccharated results in decreased expression of BCL2 protein |
| dt1203 | 91663255 | Sucroferric oxyhydroxide | 836 | CASP3 | Bos taurus (cattle) | 16957011 | Ferric oxide, saccharated results in increased cleavage of and results in increased activity of CASP3 protein|ferric oxide, saccharated results in increased expression of CASP3 protein |
| dt1204 | 91663255 | Sucroferric oxyhydroxide | 6347 | CCL2 | Homo sapiens (human) | 17699372 | Ferric oxide, saccharated results in increased expression of CCL2 protein |
| dt1205 | 91663255 | Sucroferric oxyhydroxide | 1026 | CDKN1A | Bos taurus (cattle) | 16957011 | Ferric oxide, saccharated results in increased expression of CDKN1A protein |
| dt1206 | 91663255 | Sucroferric oxyhydroxide | 7157 | TP53 | Bos taurus (cattle) | 16957011 | Ferric oxide, saccharated results in increased expression of TP53 protein |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT01438372 | IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD | PHASE2 | WITHDRAWN | Wayne State University | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Intravenous iron sucrose|DRUG: Oral ferrous… | Details |
| NCT00810030 | FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR | PHASE3 | COMPLETED | Vifor Pharma | Inflammatory Bowel Disease|Anemia|Iron Deficiency… | DRUG: Ferric carboxymaltose|DRUG: Iron Sucrose | Details |
| EUCTR2022-000894-16-NL | Predicting Response to Iron Supplementation in Patients with active Inflammatory Bowel Disease_ - PRIme | PHASE4 | Not Recruiting | Leiden University Medical Center | Inflammatory Bowel Disease MedDRA version: 20.0_… | Trade Name: Feraccru Pharmaceutical Form: Capsule… | Details |
| EUCTR2008-002333-75-DE | A multi-centre, randomised, prospective, open-label study to investigate the efficacy and safety of a standardised correction dosage regimen of intravenous ferric carboxymaltose (FERINJECT) versus iron sucrose (VENOFER) for treatment of iron deficiency anaemia in patients with inflammatory bowel disease | Not Available | Not Recruiting | Vifor (International) Inc. | Iron deficiency anaemia in patients with inflamma… | Trade Name: FERINJECT 50 mg iron/ml solution for … | Details |
| NCT01067547 | A Trial of Iron Replacement in Patients With Iron Deficiency. | PHASE4 | COMPLETED | Richard Fedorak | Iron Deficiency|Inflammatory Bowel Disease | DRUG: Iron Sucrose.|DRUG: Iron sucrose | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Association between iron deficit repletion with ferric carboxymaltose relative …
PMID: 37199058
Year: 2023
Relationship Type:
Adverse Effect
Score: 6.5
BACKGROUND: Iron deficiency and iron deficiency anemia are common in pediatric inflammatory bowel disease and often require supplementation with iron…
Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for th…
PMID: 35574429
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and i…
Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency
PMID: 32297281
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Iron deficiency and iron-deficiency anemia are associated with increased morbidity and mortality in a wide range of conditions. In many patient popul…
Iron sucrose - characteristics, efficacy and regulatory aspects of an establish…
PMID: 25186219
Year: 2014
Relationship Type:
Treatment
Score: 6.3
INTRODUCTION: Iron is a key element in the transport and utilization of oxygen and a variety of metabolic pathways. Iron deficiency is a major cause …